

Editorial Article

Personalized and Precision Medicine (Ppm) Through the View of Biomarker-Driven Applications to Support Their Global Impact in the Upgraded Healthcare-Related Services

Sergey Suchkov^{1-6,9*}, Daniel Scherman¹¹, Alan Wu¹³, Alena Borisova¹, Shawn Murphy^{7,8}, David Smith¹², and Hiroyuki Abe^{9,10}

¹Russian University of Medicine, Moscow, Russia

²The Russian Academy of Natural Sciences, Moscow, Russia

³EPMA, Brussels, EU

⁴PMC, Washington, DC, USA

⁵AMEE, Dundee, Scotland

⁶New York Academy of Sciences, USA

⁷MGH, Boston, MA, USA

⁸Harvard Medical School, Boston, MA, USA

⁹ISPM, Tokyo, Japan

¹⁰Abe Cancer Clinic, Tokyo, Japan

¹¹Centre de Recherche Pharmaceutique de Paris (CRP2); Faculté de Pharmacie, Université Paris Descartes, Paris, France

¹²Mayo Clinic, Rochester, MN, USA

¹³Dept for Pharmacogenomics, UCSF Medical School, San Francisco, CA, USA

Corresponding Author: Sergey Suchkov, Russian University of Medicine, Moscow, Russia, The Russian Academy of Natural Sciences, Moscow, Russia, EPMA, Brussels, EU, PMC, Washington, DC, USA, AMEE, Dundee, Scotland, AHA, Houston, TX, USA, ISPM, Tokyo, Japan.

Received: 📅 2024 Mar 18

Accepted: 📅 2024 May 07

Published: 📅 2024 Sep 23

Abstract

Personalized and precision medicine (PPM) relies on specific biomarkers to guide clinical decisions, distinguishing between predictive and prognostic biomarkers. Biomarkers are crucial in diagnosis, risk assessment, treatment guidance, and monitoring, with the potential to improve treatment outcomes. Biomarkers are clinically significant to a wide range of medical conditions, including cardiovascular diseases, autoimmune disorders, and neurodegenerative diseases. In cancer research, biomarkers enable risk assessment, diagnosis, prognosis determination, treatment prediction, therapy monitoring, and revolutionizing clinical decision-making. Designing trials for biomarker-guided therapy presents numerous challenges. Despite these, biomarker-guided trials are crucial for advancing personalized medicine and improving patient outcomes. New generation of biomarkers, particularly microRNAs are gathering attention into the realm of personalized and precision medicine due to their diagnostic, prognostic, and predictive biomarker potential. However, new types of biomarkers need to be researched and implemented to harness this potential. Additionally, this article discusses the integration of biomarkers into clinical practice, the direction of potential research, and the transformative impact new types of biomarkers can have on personalized medicine. Ultimately, the article emphasizes the significance of biomarker research in advancing personalized healthcare interventions, improving patient outcomes, and reshaping the healthcare landscape.

Keywords: Biomarker, Biomarker classification, Clinical trial, Companion diagnostics (CDx), Drug development, Personalized and Precision Medicine, Personalized treatment, Bio design, Predictive biomarker, Prognostic biomarker.

Abbreviations

PPM: Personalized and Precision Medicine;
 CFTR: Cystic Fibrosis Transmembrane Conductance Regulator;
 HLA: Human Leukocyte Antigen Allele;
 HIV: Human Immunodeficiency Virus;
 PSA: Prostate-Specific Antigen;
 COPD: Chronic Obstructive Pulmonary Disorder;
 CRP: C-Reactive Protein;
 EGFR: Epidermal Growth Factor Receptor;
 PPO: Personalized and Precision Oncology;
 miRNAs: microRNAs;
 CTCs: Circulating Tumor;
 CPAN: Cancer Protein Association Network;
 PPI: Protein-Protein Interactions;
 NBBs: Network-Based Biomarkers;
 Abs: Antibodies;
 Cat Abs: Catalytic Activity Antibodies;
 MS: Multiple Sclerosis

1. Introduction

The area of personalized and precision medicine (PPM) as an upgraded model of healthcare services is an area of daily clinical practice, that involves the use of measuring specific and/or targeted biomarkers as an area of clinical interest. The success in the management of disorders directly depends on the stage of the pathological process, and a wide range of biomarkers, due to their high specificity, can diagnose a disease and/or predict the risks of its development at the preclinical stage with almost 100% probability. Meanwhile, marker molecules are used to determine, in particular, the state of cell damage processes, a number of functionally important biomolecules, as well as the presence of metabolites or precursor proteins, which are detected thanks to innovative OMICS-technologies such as genomics, proteomics, transcriptomics and metabolomics (Fig. 1).




Figure 1: Personalized & Precision Medicine (PPM) in Revolutionizing Healthcare [1].

PPM-guided healthcare is a key area of focus, combining pioneering science, data, analytics and technology to advance new discoveries and improve patients' lives. The approach of PPM and PPM-guided healthcare recognize that each person's genetic and biological composition is distinct, and therefore, their response to treatment can vary significantly. These approaches take into account an individual's unique genetic makeup, environmental, and lifestyle factors to offer tailored medical interventions. PPM-guided healthcare encompasses an approach to patient care that takes into

account not only their genetic characteristics but also factors such as preferences, beliefs, attitudes, knowledge, and social context. On the other hand, PPM refers to the healthcare delivery model that heavily relies on data, analytics, and information to yield targeted and accurate treatments. By leveraging the patient's genetic characteristics, PPM holds the potential to provide tailored drugs at precise dosages and optimal timings, thus boosting efficiency in medical practice and reducing healthcare expenses. PPM adopts a more nuanced strategy, taking both genotypic and phenotypic differences into account, in order to create a therapy or preventative method that may be used to benefit both populations and individuals. The progress in PPM is leading to tangible advantages, including the ability to detect illnesses at an early stage and create personalized treatment plans. The personalized care made possible by precision medicine relies on various data collection and analytics technologies. Notably, the integration of high-throughput genotyping with the widespread use of electronic health records presents an unparalleled opportunity for scientists to extract novel phenotypes from real-world clinical and biomarker data [5].

Biomarkers play a crucial role in understanding and monitoring the intricacies of the human body. They offer valuable insights into biological processes, disease diagnosis, treatment effectiveness, and patient outcomes, enabling researchers and clinicians to make informed clinical decisions. The identification of biomarkers to support decision-making is central to PPM, in clinical scenarios. The difference between a biomarker's prognostic and predictive value can be highly useful in charting a treatment plan for patients and determining treatment outcomes (Fig. 2).




Figure 2: Application of Pattern-related Biomarker in Personalized & Precision Medicine (PPM) [2].

The role of biomarkers in the development of PPM provides a strategic opportunity for technological developments to improve human health and reduce health-care cost. PPM as a concept concerns the adjustment of treatments to individual or subgroups of patients based on the use of disease-specific biomarkers. Biomarkers are valuable for predicting prognosis and dose selection. Moreover, they may be helpful in detecting therapeutic and adverse responses and in patient stratification based on efficacy or safety prediction. Thus, biomarkers are essential tools for the selection of appropriate patients for treatment with certain drugs to and enable

PPM, that is 'providing the right treatment to the right patient, at the right dose at the right time'. Prognostic biomarkers are of particular significance for malignant conditions. Similarly, diagnostic biomarkers are important in autoimmune diseases. Identification, qualification and implementation of the different kinds of biomarkers are challenging and frequently necessitate collaborative efforts. This is particularly true for stratification biomarkers that require a companion diagnostic marker that is co-developed with a certain drug. There continues a great debate as to the overall success of this personalized process to identify actionable molecular targets to pinpoint therapies. These and other approaches have resulted in the development and use of over a dozen specific biomarkers and therapies for cancer treatment that have FDA approval. In addition, there are many applications of disease-specific biomarkers to promote PPM in addition to cancer diagnostics and therapies.

PPM relies on validated biomarkers with which to better classify patients by their probable disease risk, prognosis and/or response to treatment. The challenge of PPM can be seen in two halves: identifying predictive biomarkers and prognostic markers. Identifying predictive biomarkers, which guide the development/use of tailored therapies - among common predictive biomarkers, such as in cystic fibrosis transmembrane conductance regulator (CFTR) mutations that can identify patients who respond more favorably than others to particular treatments; human leukocyte antigen allele (HLA)-B*5701 genotype to evaluate HIV patients before the onset of abacavir treatment to identify patients at risk for severe skin reactions; [3]; breast cancer genes BRCA 1 and 2 mutations as a predictive biomarker to identify patients (women with platinum-sensitive breast cancer), who are likely to respond to ADP-ribose-PARP inhibitors [4]. Identifying prognostic markers, which guide other aspects of care and clinical trial planning, i.e. prognostic markers can be considered as covariates for stratification - breast cancer genes, BRCA 1 and 2, as prognostic biomarkers that can help determine the likelihood of recurrence of breast cancer; prostate-specific antigen (PSA) as a prognostic biomarker for assessing disease progression in prostate cancer patients; plasma fibrinogen can be used as a prognostic biomarker for patients with the chronic obstructive pulmonary disorder (COPD) to determine risk for exacerbation; C-reactive protein (CRP) as a prognostic biomarker that can be used for patients with a history of myocardial infarction or unstable angina to identify risk of recurrent coronary artery disease [5].

The rapid development of computation biology, systems biology, and multi-OMICS is driving the development of pattern recognition to discover reliable molecular pattern biomarkers for biomarker-driven targeted treatment [6].

1.1. Biomarker Categories in Clinical Practice

To establish whether a marker is purely prognostic, it needs to be demonstrated that there is a strong association between biomarker-related profile and the outcome, regardless of treatment. The latter can be used in diagnostics, as well as in assessment of disease severity, risk stratification,

prediction, guide clinical decisions, and help pick appropriate treatment, modify therapy, and response to it. In this review, we will analyze what characteristics a biomarker should have and how to ensure its usefulness, and we will review the biomarkers that in our opinion can make their knowledge more useful to the reader in their clinical practice, with a future perspective. Finally, a biomarker may have both predictive and prognostic implications [7].

In a broader strategic sense demonstrating the evidence-based clinical value, there are key categories of biomarkers (Fig. 3A, B), including:

1. diagnostic biomarkers: to identify individuals with a disease or condition of interest or to define a subset of the disease;
2. prognostic biomarkers: indicate the likelihood of a clinical event, disease recurrence, or progression;
3. predictive biomarkers: to identify individuals who are likely to experience a favorable or unfavorable effect from a specific intervention or exposure;
4. safety biomarkers;
5. Pharmacodynamic (response) biomarkers;
6. monitoring biomarker;
7. Susceptibility (risk) biomarkers [8].




Figure 3A: Classification of Biomarkers Based on Its Main Clinical Application [9].

Biomarkers are critical to the rational development of medical therapeutics, but significant confusion persists regarding fundamental definitions and concepts involved in their use in clinical practice, particularly in the fields of chronic disease and nutrition. Clarification of the definitions of different biomarkers and a better understanding of their appropriate application could result in substantial benefits. The use of biomarkers as pre-early (subclinical) warning systems in the evaluation of disease risk has increased markedly in the last decade. Biomarkers are indicators of typical biological processes, pathogenic processes, or pharmacological reactions to therapy. The application and identification of biomarkers in the medical and clinical fields have an enormous impact on society. Advancements in OMIVS technologies have opened up new possibilities to obtain novel biomarkers of different types, employing genomic strategies, epigenetics,

metabolomics, transcriptomics, lipid-based analysis, protein studies, etc. Particular biomarkers for specific diseases, their prognostic capabilities, and responses to therapeutic paradigms have been applied for screening of various normal healthy, as well as diseased, tissue or serum samples, and act as appreciable tools in pharmacology and therapeutics, etc. Moving our focus from the treatment of late-stage diseases to the monitoring and management of diseases caught at an pre-early stage, will perhaps move medicine from a curative model to one of prevention.




Figure 3B: Predictive and Prognostic Biomarkers in Personalized & Precision Medicine.

Biomarkers play an important role in the detection and management of patients and pre-illness persons-at-risk. For instance, prognostic biomarkers enable identification of patients with a more aggressive tumor evolution, while predictive biomarkers permit the identification of patients with a higher probability of responding or not to a specific treatment. To demonstrate that a biomarker is predictive of treatment benefit, the study requires biomarker status on all patients as well as patients who were treated with the agent of interest and patients not so treated, preferably in the context of a randomized study. A formal statistical test of the treatment-by-biomarker interaction should be significant. To establish whether a marker is purely prognostic, it needs to be demonstrated that there is a significant association between the biomarker and outcome, regardless of treatment, and that treatment effects do not depend on the biomarker.

Analyzing and assessing the above-mentioned diagram, stress that predictive and Pharmacodynamic biomarkers would play a crucial role in identifying patients or persons at risk who are more likely to respond favorably to specific treatments [10]. By unraveling the underlying molecular mechanisms associated with treatment response, these biomarkers pave the way for targeted interventions, optimizing treatment outcomes and minimizing unnecessary adverse effects. For instance, the identification of EGFR-related mutations in lung cancer, determines the response to EGFR in-

hibitors, leading to improved treatment efficacy and patient survival rates. The advent of those biomarkers has revolutionized the field of PPM, where treatments are tailored to individual patients based on their unique disease characteristics. By providing insights into the likelihood of treatment response, predictive biomarkers empower clinicians to make informed decisions and optimize therapeutic interventions [11].

In contrast to the fully validated and FDA-approved biomarkers, many exploratory biomarkers and biomarker candidates have potential applications. Prognostic biomarkers are of particular significance for malignant conditions and monitoring cancer-related conditions. Similarly, canonical diagnostic biomarkers are important in autoimmune diseases. Disease severity biomarkers are helpful tools in the treatment for chronic inflammatory diseases. Identification, qualification, and implementation of the different kinds of biomarkers are challenging and frequently necessitate collaborative efforts. This is particularly true for stratification biomarkers that require a companion diagnostic marker (theranostic) that is co-developed with a certain drug [12].

Theranostics is considered a fusion of diagnosis and medication. It helps to optimize the rationalization of safety, effective results and overall drug development. The latter in the future of PPM, being and serving as a valuable guidance, would play a crucial role in clinical practice since possessing their accuracy is crucial for the success of the therapeutic, preventive, prophylactic, and rehabilitative choice (Fig.4A, B).




Figure 4 A: From Companion Diagnostics to Theranostics: A New Avenue for Personalized and Precision-driven Approaches [13].

There is a growing paradigm within the frame of PPM about a shift toward integrating therapeutics and diagnostics rather than developing and deploying them separately. In this gradual move toward more effective and PPM-guided medications, companion diagnostics are an intermediate stage. The next step may be “theranostics”, in which single chemical entities are developed to deliver therapy and diagnosis simultaneously. This approach involves targeted and cell-specific therapy, controlled drug release, personalized dosage forms, wearable drug delivery, and companion diagnostics. By integrating cutting-edge technologies with drug deliv-

ery systems, greater precision can be achieved at the tissue and cellular levels through the use of stimuli-responsive nanoparticles, and the development of electrochemical sensor systems. This precision targeting – by virtue of nanotechnology – allows for therapy to be directed specifically to affected tissues while greatly reducing side effects on healthy tissues. Companion diagnostics enable efficient monitoring of treatment response, enabling customized adjustments to the treatment plan. The concept of theranostics is well illustrated in PPM-driven oncology and refers to the development of molecular diagnostic tests and targeted therapeutics in an interdependent, collaborative manner with the goals of individualizing treatment by targeting therapy to an individual's specific disease subtype and genetic profile. This strategy will enable optimization of drug efficacy and safety and will assist in streamlining the drug development process.




Figure 4B: From Companion Diagnostics to Theranostics: A New Avenue for Personalized and Precision-Driven Approaches [14].

In the era of PPM, diagnostic approaches are helping pharmaceutical and biotechnology sponsors streamline the clinical trial process. Molecular assays and diagnostic imaging are routinely being used to stratify patients for treatment, monitor disease, and provide reliable early clinical phase assessments. The importance of diagnostic approaches in drug development is highlighted by the rapidly expanding global cancer diagnostics market and the emergent attention of regulatory agencies worldwide, who are beginning to offer more structured platforms and guidance for this area. In vitro companion diagnostic assays and in vivo molecular diagnostic imaging continue to advance the field of PPM and are changing the way in which clinicians are treating cancer and other human diseases. Assays and imaging agents are being developed alongside therapeutics to stratify patients and maximize the potential treatment benefit of new oncology therapeutics. These approaches are not only changing the landscape of clinical trials, but are also contributing to important changes in drug development and treatment. With the discovery of new oncology targets and imaging tracers

comes increased capabilities to probe, monitor, and evaluate cancer on a molecular level. It is clear that more widespread implementation of imaging diagnostic tools will advance oncology clinical trials and help support new drug approvals in this rapidly expanding therapeutic area.

Efforts to discover next-generation biomarkers for clinical use have been significant, yet their implementation remains low [15-17]. PPM leverages advanced biomarker-driven technologies to inform evidence-based decisions across disease diagnosis, treatment, prediction, prevention, and prophylaxis. Utilizing molecular stratification, PPM enhances medication selection, reduces adverse effects, and shifts focus from reaction to prevention [18, 12]. Biomarkers derived from genes, proteins, and interactomes play a pivotal role in predicting individual responses to therapies and guiding personalized treatment strategies. Questions persist regarding best practices for extracting prioritized biomarkers in PPM-driven research, amidst the era of OMICS-technologies and Big Data. Biomarkers are integral to the development of PPM-driven technologies, aiding in clinical decision-making, medical product development, and drug discovery. They serve as indicators of normal and pathogenic processes, contributing to drug target selection, patient stratification, and safety assessment in drug development [15, 19].

The molecular heterogeneity of living systems offers a rich source of candidate biomarkers, necessitating controlled error rates in statistical models. Biomarkers can signify various health or disease characteristics, acting as indicators of disease trait, state, or progression. Relevant biomarkers define patient subgroups, informing evidence-based medical decisions [20-22]. Expectations for precision tools like PSA and specific gene mutations are heightened by the potential of Big Data to translate into clinically relevant information [23].

1.2. Biomarkers and Personalized and Precision Oncology (PPO)

Biomarkers are extremely important in cancer research and Personalized and Precision Oncology (PPO). They are crucial for risk assessment, screening, differential diagnosis, prognosis determination, prediction of disease recurrence and response to therapy, and progression monitoring [11, 24, 25]. With cutting-edge proteomic and genomic technologies, DNA and tissue microarrays, gel electrophoresis, mass spectrometry, and protein assays, as well as improved bioinformatics tools, the evolution of biomarkers to reliably assess the results of cancer mitigation and therapy is now possible. Looking forward, a urine or a serum test for each stage of cancer may drive clinical decision-making, complementing, or even replacing presently available invasive methods [15, 26]. Predictive biomarkers help to optimize therapy decisions, as they provide information on the likelihood of response to a given chemotherapeutic. Among the prognostic factors that identify patients with different outcome risks (e.g., recurrence of the disease), the following factors can be distinguished: somatic and germline mutations, changes in DNA methylation that lead to the enhancement or suppression of gene expression, the occurrence of elevat-

ed levels of mi-croRNA (miRNA) capable of binding specific messenger RNA (mRNA) molecules, which affects gene expression, as well as the presence of circulating tumor cells (CTCs) in blood, which leads to a poor prognosis for the patient. Biomarkers for personalized oncology are used mainly in molecular diagnostics of chronic myeloid leukemia, colon, breast and lung cancer, and recently in melanoma. They are successfully used in the evaluation of the benefits that can be achieved through targeted therapy or in the evaluation of toxic effects of the chemotherapeutic used in the therapy [27, 28].




Figure 5: The Use of Various Types of Biomarkers on the Example of Melanoma [29].

Due to the individualization of cancer therapy, the identification of cancer- and oncology-specific biomarkers has become a foremost goal for cancer researchers [2, 15]. The common usage of PSA in prostate cancer screening has prompted investigators to look for appropriate biomarkers for screening other kinds of cancer. Targeted medicines, such as Iressa® (gefitinib), Gleevec® (imatinib), and Herceptin® (trastuzumab), are currently available and may benefit from a more targeted treatment based on diagnostic testing. Clinically, cancer-related families of biomarkers may help identify individuals who are most likely to react to a medication, enable real-time monitoring of treatment effectiveness, or detect early indications of drug toxicity. Furthermore, biomarkers are heavily used in go/no-go decision-making throughout the drug development cycle, from early discovery to preclinical assessment. Meanwhile, with the emergence of more sensitive and specific technologies that are now able to be run in clinical settings and the ability to accurately measure biomarkers, there is a need to understand how biomarkers are defined, and how they are used in conjunction with drug treatment or with the frame of protocols of clinical trials [30].

1.3. Biomarkers of the Next Step Generation

Meanwhile, a principally new generation of biomarkers is required that define all aspects of the variability of unified system indicators. For instance, miRNAs circulating are attracting interest in the burgeoning field of PPM and associated subfields, with data supporting their diagnostic, prognostic, and predictive biomarker potential. MicroRNAs (miRNAs) are small non-coding RNA molecules, which modulate ge-

netic expression and which in recent years have emerged to have enormous potential as biomarkers. A schematic diagram showing miRNA biogenesis, modes of their secretion into body fluids, RNA extraction and quantitative approaches. In future, clinical decisions may be made based on the expression levels of miRNAs (Fig. 6) [22].

The tight association of miRNAs with several cancer-related processes makes them undoubtedly connected to the effect of specific cancer drugs inducing either resistance or sensitization. In this context, personalized medicine through miRNAs arose recently with the discovery of single nucleotide polymorphisms in the target binding sites, in the sequence of the miRNA itself, or miRNA biogenesis-related genes, increasing risk, susceptibility, and progression of multiple types of cancer in different sets of the population. miRNA markers show that they can enable a wide range of diseases to be diagnosed before clinical symptoms are manifested, and they can help to assess a patient's response to therapy to correct and personalize treatments.

The depicted scenario implies that the overall variation displayed by these small non-coding RNAs has an impact on patient-specific pharmacokinetics and pharmacodynamics of cancer drugs, pushing on a rising need for personalized treatment. Indeed, miRNAs from either tissues or liquid biopsies are also extensively studied as valuable disease biomarkers for early recognition, progression, and prognosis. Despite the lack of standardized protocols regarding the use of miRNAs in current clinical practice, they constitute a reliable tool for future use. These molecules meet most of the required criteria for being an ideal biomarker, such as accessibility, high specificity, and sensitivity. Effective miRNA profiling calls for reproducible, sensitive, and specific tools with turn-around times fast enough to support bio design-inspired translational research and applications into what can be a rapidly changing disease progression and treatment environment. Circulating miRNAs became one of the most promising biomarkers in oncology for early diagnosis, prognosis, and therapeutic response prediction [32, 33].




Figure 6: Circulating microRNAs as biomarkers [31].

miRNAs are a subset of non-coding RNAs that regulate the expression of a multitude of genes post-transcriptionally and thus are potential diagnostic, prognostic, and predictive biomarkers and have also emerged as potential therapeutics. Because miRNAs are involved in the post-transcriptional regulation of their target mRNAs via repressing gene expression, defects in miRNA biogenesis pathway and miRNA expression perturb the expression of a multitude of oncogenic or tumor-suppressive genes that are involved in the pathogenesis of various cancers. As such, numerous miRNAs have been identified to be downregulated or upregulated in many cancers, functioning as either oncomiRNAs or oncosuppressor miRNAs. Moreover, dysregulation of miRNA biogenesis pathways can also change miRNA expression and function in cancer. Profiling of dysregulated miRNAs in pancreatic cancer has been shown to correlate with disease diagnosis, indicate optimal treatment options and predict response to a specific therapy. Specific miRNA signatures can track the stages of pancreatic cancer and hold potential as diagnostic, prognostic, and predictive markers, as well as therapeutics such as miRNA mimics and miRNA inhibitors (antagomirs). MicroRNAs (miRNAs) are a particularly attractive class of biomarkers as they are not only resistant to the high levels of RNases found in biological fluids, but also able to confer clinically useful information about the disease relating to diagnosis, prognosis, and the response to treatment. Circulating miRNAs are either associated with proteins or extracellular vesicles (EV) and although their origin and implied functions as intracellular messengers remain somewhat controversial, they are implicated in the progression and the establishment of metastatic niches. The identification of miRNAs as biomarkers provides possibilities for development of less or non-invasive and more specific methods for monitoring tumor growth and progression.

1.4. Circulating tumor cells (CTCs) in clinical practice

The other example of the next step generation biomarkers is circulating tumor cells (CTCs), illustrating subclinical stages and predictive risks as applicable to tumor progression [34]. CTCs as a biomarker of the latest generation would make up a minute fraction of the total number of cells circulating in blood. CTCs can be released from the primary tumour into the bloodstream and may colonize distant organs giving rise to metastasis (Fig. 7) [32, 35].




Figure 7 : Key Steps in The Formation of Metastases by CtcS [34].

Analysis of circulating tumor cells (CTCs) collected from patient's blood offers a broad range of opportunities in the field of PPM-driven oncology. With new advances in profiling technology, it is now possible to demonstrate an association between the molecular profiles of CTCs and tumor response to therapy. CTCs are good candidates for generating preclinical models, making it possible to follow up the spatial and temporal heterogeneity of tumor tissues. This method is a non-invasive liquid biopsy that can be obtained at any stage of the disease. CTCs play a crucial role in metastasis and became an emerging topic in today's cancer research. In addition, the analysis of CTCs in liquid biopsies will be a valuable tool for prognosis prediction and real time therapy monitoring. The characterization of CTCs may open up a new field of treatment strategy to prevent metastasis or maintain a stable disease. CTCs may be useful for individualized drug susceptibility testing and are thus believed to be responsible for the development of metastatic disease. Understanding CTC biology requires innovative technologies for the isolation of these rare cells. The analysis of CTCs is an outstanding tool to provide insights into the biology of metastatic cancers, to monitor disease progression and with potential for use in liquid biopsy-based personalized cancer treatment. For instance, through single-cell-resolution genomics and transcriptomics, it is becoming increasingly clear that CTCs are heterogeneous at multiple levels and that only a fraction of them is capable of initiating metastasis. CTCs adopt multiple ways to enhance their metastatic potential, including homotypic clustering and heterotypic interactions with immune and stromal cells. On the clinical side, both CTC enumeration and molecular analysis may provide new means to monitor cancer progression and to take individualized treatment decisions, but their use for early cancer detection appears to be challenging compared to that of other tumor derivatives such as circulating tumor DNA.

CTCs as a kind of cellular biomarker that is detected in patients with early stage cancers and, owing to their association with metastasis, might indicate the presence of aggressive disease, thus providing a possible means to expedite diagnosis and treatment initiation for such patients while avoiding overdiagnosis and overtreatment of those with slow-growing, indolent tumors. It is estimated that more than 90% of cancer mortality is caused by distant metastasis. Investigating CTCs provides important tumor information since these cells are already related to metastatic disease; broken free from the tumor mass, transited through interstitial tissues, and intravasated into the vasculature. Understanding and counteracting this process is essential to managing cancer. The utility of CTCs as an early diagnostic tool has been investigated and confirmed (Fig. 8A-C).




Figure 8A: Clinical Applications of Single-Cell Analysis of Circulating Tumor Cells [34].




Figure 8B: Clinical Applications of Single-Cell Analysis of Circulating Tumor Cells (Ctcs) Ctc Expressing Her2 / Er Biomarkers [36].




Figure 8C: Clinical Applications of Single-Cell Analysis of Circulating Tumor Cells (Ctcs) - Highly Sensitive Ctc Detection from Triple Negative Breast Cancer Patient [36].

1.5. Catalytic Antibodies or Abzymes

Novel biomarkers may also identify specific pathways involved in risk, where drugs interrupting such mediator bio

targets have not yet been explored in appropriately designed trials [30,37,26]. Regarding biomarkers of the latest innovative trends, let me add that along with canonical antibodies (Abs) serving a crucial role as biomarkers in clinical settings, some of the Ab-based families are Abs possessing with catalytic activity (cat Abs or abzymes) and thus belong to Abs with a feature of functionality [38].

The immune system provides a highly evolved natural process to generate one class of complex biomarkers-the antibodies. A combination of the two could be exploited to generate new classes of molecules with novel functions. A catalytic antibody is a sort of natural artificial enzyme - it is a natural protein synthesized by the usual biological processes and is intended to catalyze a reaction for which no real enzyme is available [39].

Cat Abs (or abzymes) are multivalent Igs, presumably of IgG isotype, endowed with a capacity to hydrolyze Ags. The enzymatic activity is located in the Fab fragment of the Ig molecule, which endows such antibodies with the ability to bind to specific antigens and hydrolyze them. Proteolytic Abs (or Ab-proteases) represent a significant portion of the family of abzymes that PPM uses to target specific Ags (Fig 9).

Because of their Ag specificity, Ab-proteases also may be used as biomarkers able to control autoimmune disease progression to transform from subclinical into clinical stages, and to predict complications. Moreover, sequence-specific Ab-proteases have proved to be greatly informative and thus valuable as biomarkers to monitor autoimmune diseases at both subclinical and clinical stages while demonstrating their predictive value for the development of the disorder [40-42].




Figure 9: Antibodies Possessing with Catalytic Activity (cat Abs or abzymes) [40].

Catalytic antibodies made it feasible to develop new catalysts, which had previously been the subject of research. These antibodies are widely used in chemistry, biology, and clinical medicine. Catalytic antibodies can continue to play a role and even fully prevent the emergence of autoimmune disorders, especially in the field of infection and immunity, where the process of its occurrence and development often

takes a long time. Natural abzymes with proteolytic (prota-bzymes) and DNA-hydrolyzing DNA-abzymes) activity are of the greatest interest. The most impressive example of the catalytic activity of protabzymes is hydrolysis of specific proteins, revealed in patients with autoimmune diseases, such as bronchial asthma (vasoactive intestinal neuropeptide), autoimmune thyroiditis (thyroglobulin), multiple sclerosis (myelin basic protein), and autoimmune myocarditis (cardio myosin). The pathogenic role of DNA-abzymes is valuable for monitoring systemic autoimmune conditions, and they are present a powerful regulator of apoptosis and other cytotoxicity mechanisms in systemic autoimmune diseases and tumors. The most promising is use of abzymes as illness activity markers, and as therapeutic agents capable of catalyzing specific proteins or activating antitumoral chemotherapeutic preparations. The therapeutic and diagnostic uses of abzymes are currently being explored, and we expect that some of them will become major clinical resources in the future.

1.6. Network-based Biomarkers (NBBs)

Moreover, following the clinical aims and objectives of the next step generation and having a complete understanding of a drug's pathway, interactome, and network interactions could expedite the identification of sensitizing mutations, drug interactions, or the risks of drug combinations to guide biomarker discovery, including simple, combinatorial, and network-based biomarkers (NBBs). Today the experts may also identify specific pathways and interactome-based networks involved in diseases for which drugs have not yet been explored in appropriately designed trials, and being set up for: normal (physiological) and pathological conditions (Fig. 10 A, B).




Figure 10 A, B: The Interactome-based Networks of Leukemia [43].

Great efforts have been undertaken in search of diagnostic biomarkers of leukemia. But individual molecules are not necessarily sensitive diagnostic indicators. Network biomarkers (NBBs) are considered to outperform individual molecules in disease characterization. The final network was further integrated with gene expression profiles to identify active modules with leukemia relevance. And the candidate NBB was evaluated for the diagnosing performance. A network of 97 genes and 400 interactions was identified for accurate diagnosis of leukemia. Functional enrichment analysis revealed that the network biomarkers were enriched in pathways in cancer. The NBBs could discriminate leukemia samples from the normal controls more effectively than the

known biomarkers. The NBBs provide a useful tool to diagnose leukemia and also aids in further understanding the molecular basis of leukemia.

Those networks may serve as sources of network-based biomarkers (NBBs) to secure diagnostic, predictive, prognostic and monitoring-related aims and objectives of the next step generation. In this sense, NBBs help determine the probability of developing chronic pathologies, autoimmunity, or cancer-predisposed conditions. Key factors contributing to the growth of the global NBBs-related healthcare services market include high prevalence of chronic autoimmune diseases and cancer; rising adoption of biomarkers for diagnostic, predictive, and prognostic applications, as well as increasing application in drug discovery and development. A NBB using constructed protein association networks is a useful tool to highlight the pathways and mechanisms of the lung carcinogenic process and, more importantly, provides potential therapeutic targets to combat cancer. From a systems perspective, the constructed network-based biomarker further evaluated the targeted carcinogenic process by the use of significant protein identification and diagnostic evaluation. More importantly, the significant proteins identified by the NBBs give mechanistic insights into the carcinogenic process and provide potential therapeutic targets to combat cancer in daily clinical practice of medicine [44].

1.7. Biomarker-guided clinical trial design

Innovative clinical trial designs are needed to address the difficulties and issues in the development and validation of biomarker-based personalized therapies. Designing trials of biomarker-guided therapy has many challenges, including:

1. Being almost always unblinded, they are prone to bias;
2. The control group, most frequently the 'usual care' group, is opened to contamination and has inevitably better outcomes than in real non-trial 'usual care';
3. Being per essence 'strategy-trials' rather than simple intervention trials, causality is difficult to establish;
4. Therapy optimization as a result of a change in the tested biomarker may be left to the decision of the investigator, only instructed to follow best guideline medical therapy, or decided per protocol using more or less sophisticated algorithms, which, although guideline-based, may vary according to the protocol [30, 45].

Validated biomarkers are essential for improving diagnoses, molecular targeted therapy, and therapeutic benefits across various diseases. Despite recent progress, the path to clinically validated biomarkers remains challenging, often creating a gap between research and application. [46].

Clinical trials are necessary to confirm the properties of emerging treatments and associated biomarkers, influencing daily clinical practices and regulatory reporting before professional or commercial release. Biomarkers also play a role in facilitating drug repurposing and guiding patient care decisions within clinical settings and drug development processes. The involvement of biomarkers in clinical practices will be more and more common in the next 5–10 years because of the development in medical-related biological and

transdisciplinary research, as well as in biodesign-inspired and biotech-driven translational applications. More clinical questions need to be answered about the biomarker and its role in the disease process and therefore more biomarker-related clinical trials will be designed to answer those specific questions. More flexible trials serving multiple purposes are expected due to the intricate relationship between biomarkers and the disease.

1.8. Future Applications of Biomarkers in Healthcare

Biomarkers are indicators of typical biological processes, pathogenic processes, or pharmacological reactions to therapy. And you might see from the above-mentioned, that biomarkers can be used, along with tools in clinical practice, as drug development tools and can be incorporated into drug development through the drug approval process, scientific community consensus followed by regulatory acceptance, and biomarker qualification. This would offer a new way to optimize treatment, decrease rehabilitation costs, and facilitate building new products and services in this area.

Numerous compounds have been tested as potential biomarkers for multiple possible applications within PPM-guided care but none is or will ever be sufficiently specific or sensitive for the heterogeneous syndromes of critical illness. New technology and access to huge patient databases are providing new biomarker options and the focus is shifting to combinations of several or multiple biomarkers rather than the single markers that research has concentrated on in the past. Biomarkers will increasingly be used as part of routine clinical practice in the future, complementing clinical examination and physician expertise to provide accurate disease diagnosis, prediction of complications, personalized treatment guidance, and prognosis. For instance, biomarkers, defined as alterations in the constituents of tissues or body fluids, provide a powerful approach to understanding the spectrum of cardiovascular diseases and chronic autoimmune myocarditis with applications involving screening, diagnosis, prognostication, prediction of disease recurrence, and therapeutic monitoring. The unique diagnostic potential of specific biomarkers and their efficacy correlates with phenotypical expression, covering neuro inflammation and neurodegeneration, including the applications of biomarker-based strategy in multiple sclerosis (MS), Parkinson and Alzheimer diseases. A comprehensive understanding of the relevance of each cancer biomarker will be very important not only for diagnosing the disease reliably, but also help in the choice of multiple therapeutic alternatives currently available that are likely to benefit the patients. Cancer biomarkers are broadly categorized into three divisions based on the specific association with diagnostic, diagnostic, predictive and prognostic biomarkers.

The therapeutic potential of different biomarkers and their use in clinical trials has also been discussed. Since the use of biomarkers as the pre-early (subclinical or pre-illness) warning systems in the evaluation of disease risk has increased markedly in the last decade. And thus the application and identification of biomarkers in the medical and clinical fields have an enormous impact on society. Despite

the recent advancements, a comprehensive approach in biomarker biogenesis is required to integrate the available information and to translate them as tools of prognostic and diagnostic potential.

1.9. Biomarkers of the Future Would be used for:

1. Screening the general population or individuals at risk (panels of screening and predisposition biomarkers);
2. The detection of the presence of a particular type of cancer (panels of diagnostic and prognostic biomarkers) [46].
3. Monitoring the progression of autoimmune inflammation, and predicting the complications and outcome (panels of prognostic biomarkers) [47].
4. Understanding whether a patient will benefit from a specific drug treatment (panels of predictive biomarkers);
5. Evaluating the drug's efficacy and optimizing the treatment, providing the tool to tailor treatment for individual autoimmunity-related patients or persons at risk (panels of pharmacodynamics biomarkers).

Meanwhile, a number of limitations of multimarker-based panels should be acknowledged. These include potential multiplexing and analytical challenges in assaying multiple biomarkers at once as well as the challenges of interpretation for the clinician due to different cut-offs for each of the separate markers [20]. Nevertheless, it can be anticipated that scoring calculators and algorithms will increasingly use circulating biomarkers in combination with clinical variables to allow appropriate surveillance and fully informed counselling of the patients, persons-at-risk, their families and other stakeholders in the process of patient care.

2. Conclusion

Biomarkers have gained significant scientific and clinical importance in the realm of PPM and related fields, offering potential benefits throughout the disease process. The oncology segment is the largest area for biomarker growth. Biomarkers can be used for early detection, estimate prognosis, guide selection of targeted therapies (companion diagnostics), and monitor response to treatment. The increased demand for rapid and accurate diagnostic OMICS-tools, an increase in the global cancer burden, and an unmet need for more specific, personalized, therapeutic targets for cancer patients and pre-cancer persons-at-risk will continue to drive growth in the market, which is really growing. The current value of the global biomarkers market is estimated to be USD 43.1 billion, with an expected compound annual growth rate (CAGR) of 12.6% from 2021 to 2026 (Figure 11).




Figure 11: Global Biomarker Market Size and Growth Forecast.

The diagnostics segment of the global biomarker market is estimated to register the fastest CAGR over the forecast period. The predicted growth is owed to advances in early diagnosis and improvement in the rate of the diagnosis. From: Biomarkers Market, available at marketsandmarkets.com

The key factors boosting market growth are:

- (i). N ageing population and increasing prevalence of chronic diseases;
- (ii). Advancements in the tools and OMICS technology used to discover and develop biomarker-based diagnostics.

Biomarkers play crucial roles in diagnosis, staging, treatment selection, and monitoring of diseases and their complications. Advances in OMICS-technologies have led to the identification of numerous candidate biomarkers with clinical potential. Integrating these biomarkers into evidence-based medical practice using emerging high-throughput technologies is essential for personalized treatment and disease prevention. Additionally, biomarker research in autoimmunity and cancer is focused on identifying predictors of successful drug-free remission and uncovering molecular similarities between seemingly distinct diseases. Shifting focus from late-stage disease treatment to early-stage monitoring and prevention could transform medicine, with collaboration across academia, industry, and other sectors vital for realizing the full potential of biomarkers in personalized medicine.

References

1. <https://www.medznat.ru/en/practice/medical-billing/precision-and-personalized-medicine-unlocking-the>
2. Zhan, X., Zhou, T., Cheng, T., & Lu, M. (2019). Recognition of Multiomics-Based Molecule-Pattern Biomarker for Precise Prediction, Diagnosis, and Prognostic Assessment in Cancer. In *Bioinformatics Tools for Detection and Clinical Interpretation of Genomic Variations* (p. 53). IntechOpen.
3. Ma, J. D., Lee, K. C., & Kuo, G. M. (2010). HLA-B* 5701 testing to predict abacavir hypersensitivity. *PLoS currents*, 2.
4. Faraoni, I., & Graziani, G. (2018). Role of BRCA mutations in cancer treatment with poly (ADP-ribose) polymerase (PARP) inhibitors. *Cancers*, 10(12), 487.
5. Méndez Hernández, R., & Ramasco Rueda, F. (2023). Biomarkers as prognostic predictors and therapeutic guide in critically ill patients: clinical evidence. *Journal of Personalized Medicine*, 13(2), 333.
6. García-Gutiérrez, M. S., Navarrete, F., Sala, F., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020). Biomarkers in psychiatry: concept, definition, types and relevance to the clinical reality. *Frontiers in psychiatry*, 11, 527209.
7. Chen, C. Y., Wu, K. H., Guo, B. C., Lin, W. Y., Chang, Y. J., et al. (2023). Personalized Medicine in Severe Asthma: From Biomarkers to Biologics. *International Journal of Molecular Sciences*, 25(1), 182.
8. de Nooijer, A. H., Pickkers, P., Netea, M. G., & Kox, M. (2023). Inflammatory biomarkers to predict the prognosis of acute bacterial and viral infections. *Journal of Critical Care*, 78, 154360.
9. García-Gutiérrez, M. S., Navarrete, F., Sala, F., Gasparyan, A., Austrich-Olivares, A., et al. (2020). Biomarkers in psychiatry: concept, definition, types and relevance to the clinical reality. *Frontiers in psychiatry*, 11, 527209.
10. Kraus, L. (2023). Predictive Biomarkers: Shaping the Future of Personalized Medicine. *Bi-omark J.* 9:020.
11. Rodríguez-Antona, C., & Taron, M. (2015). Pharmacogenomic biomarkers for personalized cancer treatment. *Journal of internal medicine*, 277(2), 201-217.
12. Laigle, L., Chadli, L., & Moingeon, P. (2023). Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises. *Expert Review of Clinical Immunology*, 19(3), 305-314.
13. Bolognesi, M. L., Gandini, A., Prati, F., & Uliassi, E. (2016). From companion diagnostics to theranostics: a new avenue for alzheimer's disease? *Miniperspective. Journal of Medicinal Chemistry*, 59(17), 7759-7770.
14. <https://www.openpr.com/news/1930919/theranostics-market-to-surpass-20-billion-usd-by-2027-leading>
15. Kallen, V. L., & Fernandes, B. S. (2019). Progressing towards precision psychiatry: current challenges in applying biomarkers in psychiatry. In *Handbook of Biomarkers and Precision Medicine* (pp. 520-528). Chapman and Hall/CRC.
16. Carrigan, P., & Krahn, T. (2016). Impact of biomarkers on personalized medicine. *New Approaches to Drug Discovery*, 285-311.
17. Kraus L. (2023). Predictive Biomarkers: Shaping the Future of Personalized Medicine. *Bi-omark J.* 9:020.
18. Moore, D. C., & Guinigundo, A. S. (2023). Biomarker-driven oncology clinical trials: novel designs in the era of precision medicine. *Journal of the Advanced Practitioner in Oncology*, 14(Suppl 1), 9.
19. Bayes-Genis, A., Voors, A. A., Zannad, F., Januzzi, J. L., Mark Richards, A., et al. (2018). Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. *European Heart Journal*, 39(30), 2793-2799.
20. Bayes-Genis, A., & Ordóñez-Llanos, J. (2015). Multiple biomarker strategies for risk stratification in heart failure. *Clinica chimica acta*, 443, 120-125.
21. Fasano, S., Milone, A., Nicoletti, G. F., Isenberg, D. A., & Ciccia, F. (2023). Precision medicine in systemic lupus erythematosus. *Nature Reviews Rheumatology*, 19(6), 331-342.
22. Sato, Y., Okamoto, K., Kawano, Y., Kasai, A., Kawaguchi, T., et al. (2023). Novel biomarkers of gastric cancer: current research and future perspectives. *Journal of Clinical Medicine*, 12(14), 4646.
23. De Sa, J., Carlson, B., Caputo, N., Vojta, D., Sandy, L., et al. (2013). Growth of molecular diagnostics and genetic testing in the USA, 2008-2011: analysis and implications. *Personalized Medicine*, 10(8), 785-792.
24. Purkayastha, K., Dhar, R., Pethusamy, K., Srivastava, T., Shankar, A., et al. (2023). The issues and challenges with cancer biomarkers. *Journal of Cancer Research and Therapeutics*, 19(Suppl 1), S20-S35.
25. Krystal-Whittemore, M., Tan, P. H., & Wen, H. Y. (2024). Predictive and prognostic biomarkers in breast tumours. *Pathology*, 56(2), 186-191.

26. Al-Dewik, N. I., Younes, S. N., Essa, M. M., Pathak, S., & Qoronfleh, M. W. (2022). Making biomarkers relevant to healthcare innovation and precision medicine. *Processes*, 10(6), 1107.
27. Chang, J. Y., & Ladame, S. (2020). Diagnostic, prognostic, and predictive biomarkers for cancer. In *Bioengineering Innovative Solutions for Cancer* (pp. 3-21). Academic Press.
28. Ladame, S., & Chang, J. (Eds.). (2019). *Bioengineering Innovative Solutions for Cancer*. Academic Press.
29. Pilla, L., Alberti, A., Di Mauro, P., Gemelli, M., Cogliati, V., et al. (2020). Molecular and immune biomarkers for cutaneous melanoma: current status and future prospects. *Cancers*, 12(11), 3456.
30. He, Pei. (2015). Personalized medicine: challenges in biomarker-related clinical trial de-sign. *Clinical Investigation*. 2015; 5:175-188.
31. Sundarbose, K., Kartha, R. V., & Subramanian, S. (2013). MicroRNAs as biomarkers in cancer. *Diagnostics*, 3(1), 84-104.
32. Armand-Labit, V., & Pradines, A. (2017). Circulating cell-free microRNAs as clinical cancer biomarkers. *Biomolecular concepts*, 8(2), 61-81.
33. Condrat, C. E., Thompson, D. C., Barbu, M. G., Bugnar, O. L., Boboc, A., et al. (2020). miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. *Cells*, 9(2), 276.
34. Lawrence, R., Watters, M., Davies, C. R., Pantel, K., & Lu, Y. J. (2023). Circulating tumour cells for early detection of clinically relevant cancer. *Nature Reviews Clinical Oncology*, 20(7), 487-500.
35. Davoudi, F., Moradi, A., Becker, T. M., Lock, J. G., Abbey, B., et al. (2023). Genomic and phenotypic biomarkers for precision medicine guidance in advanced prostate cancer. *Current Treatment Options in Oncology*, 24(10), 1451-1471.
36. RareCyte.(n.d.). Circulating Tumor Cells (CTCs). Available from: <https://rarecyte.com/circulating-tumor-cells>.
37. Chaffey, B., & Silmon, A. (2016). Biomarkers in personalized medicine: discovery and delivery. *The Biochemist*, 38(1), 43-47.
38. Silverstein, A., Dudaev, A., Studneva, M., Aitken, J., Blokh, S., et al. (2022). Evolution of biomarker research in autoimmunity conditions for health professionals and clinical practice. *Progress in Molecular Biology and Translational Science*, 190(1), 219-276.
39. Zhao, D., Chen, J., Hu, X., & Zhang, S. (2023). Catalytic antibodies: Design, expression, and their applications in medicine. *Applied Biochemistry and Biotechnology*, 195(2), 1514-1540.
40. Gabibov, A. G., Ponomarenko, N. A., Tretyak, E. B., Paltsev, M. A., & Suchkov, S. V. (2006). Catalytic autoantibodies in clinical autoimmunity and modern medicine. *Autoimmunity Reviews*, 5(5), 324-330.
41. Suchkov, S. V., Gabibov, A. G., Gnuchev, N. V., & Alekberova, Z. S. (2001). The Distribution of DNA-Abzymes in Patients with Different Types of Systemic and Organ-Specific Autoimmune Disorders. *Russian journal of immunology: RJI: official journal of Russian Society of Immunology*, 6(3), 309-312.
42. Suchkov, S. (2021). A New Generation of Translational Tools designed to Monitor Multiple Sclerosis (MS) at Clinical and Subclinical Stages. *Medicon Medical Sciences*, 1, 55-63.
43. Yuan, X., Chen, J., Lin, Y., Li, Y., Xu, L., et al. (2017). Network biomarkers constructed from gene expression and protein-protein interaction data for accurate prediction of leukemia. *Journal of Cancer*, 8(2), 278.
44. Alfano, C., Farina, L., & Petti, M. (2023). Networks as biomarkers: Uses and purposes. *Genes*, 14(2), 429.
45. Lai, T. L., Lavori, P. W., Shih, M. C. I., & Sikic, B. I. (2012). Clinical trial designs for testing biomarker-based personalized therapies. *Clinical trials*, 9(2), 141-154.
46. Chauvie, S., Mazzoni, L. N., & O'Doherty, J. (2023). A Review on the Use of Imaging Biomarkers in Oncology Clinical Trials: Quality Assurance Strategies for Technical Validation. *Tomography*, 9(5), 1876-1902.
47. Veronika Medvedeva, Eric James Sorenson, Mariya Studneva, Noel Rose, Sergey Suchkov, et al. (2022). The Autoimmune Syndrome Through the Prism of Targeted AT-Mediated Proteolysis: Innovative Ideas, Philosophy, and Tools for Practitioners of The Next Step Generation. *Am J Biomed Sci & Res*. 15(3). doi: 10.34297/AJBSR.2022.15.002114;